T45 Labs Propels Cardiovascular Start-Ups With Hands-On Strategy

Founded and managed by Marwan Berrada-Sounni, T45 Labs is more than an accelerator or incubator, eschewing both labels in favor of “specialized medical technology innovation company” to reflect its hands-on approach and narrow focus on the cardiovascular space. Recently, T45 Labs closed its oversubscribed Fund I at $25 million to support milestone achievements for three of its four portfolio companies: Advanced NanoTherapies, VahatiCor, and NuevoSono. The fourth, ReCava, will be supported by Fund II, which is currently open for investment.